Samsung NeuroLogica, MedyMatch to partner
Samsung NeuroLogica and artificial intelligence (AI) developer MedyMatch have...Read more on AuntMinnie.comRelated Reading: NeuroLogica launches mobile lung CT unit IBM Watson deal puts MedyMatch on the map Samsung lands HealthTrust deal MedyMatch debuts AI for detecting intracranial bleeding Samsung NeuroLogica adds Fla. CT installation AI developer adds to scientific, medical advisory board
The HeartMate 3 left ventricular assist system is engineered to avoid pump thrombosis, yet bleeding complications persist. We investigated the safety of low-intensity anti-coagulation in patients with the HeartMate 3.
CONCLUSION: Due to the increasing number of patients on long-term mechanical circulatory support, the chances are that physicians in the initial emergency admission are unfamiliar with these devices but need to operate them in emergency cases. Therefore, knowledge of these procedures and their complications becomes increasingly important. PMID: 29623383 [PubMed - as supplied by publisher]
In the general population, increased aortic stiffness (kAo) is associated with risk of cardiovascular events. Continuous-flow left ventricular assist device (CF-LVAD) pts have been reported to have increased kAo. The association between kAo and common adverse events (AEs), including stroke, gastrointestinal bleed (GIB) and pump thrombosis (PT) are unknown in CF-LVAD pts.
There is an increased incidence of atrial fibrillation and risk of VTE in the post-HT setting. The nuances of vitamin K antagonists, including drug/food interactions and narrow therapeutic index, limit their applicability in this patient population. The use of direct acting oral anticoagulants (DOACs) has risen dramatically due to convenience, simplified administration, and improved safety profile compared to warfarin. Despite these advantages, adoption in HT has been limited due to concerns of post-op bleeding, drug interactions, and unknown safety and efficacy.
To determine if right ventricle (RV) dysfunction is a risk factor for gastrointestinal bleeding (GIB) following left ventricular assist device (LVAD) implantation.
Pectoralis muscle mass and tissue attenuation obtained on preoperative CT scans are powerful predictors of mortality after LVAD implantation. Gastrointestinal (GI) bleeding remains a common problem on mechanical support. It is unknown whether these skeletal muscle measures, which correlate with frailty and tissue quality, are associated with the development of recurrent GI bleeding.
The HeartMate 3 Left Ventricular Assist system (LVAS) has demonstrated enhanced hemocompatibility, with absence of de-novo pump thrombosis. However, clinically observed bleeding-related adverse events continue to remain significantly burdensome. We hypothesized that the enhanced hemocompatibility of the HeartMate 3 LVAS allows the safe use of decreased anticoagulation intensity, potentially decreasing bleeding-related adverse events.
Aspirin and warfarin (ASA+warf) are used in combination for thromboprophylaxis in patients with left ventricular assist devices (LVAD). Heartmate 3 (HM3) LVAD is associated with low risk of pump thrombosis. We studied the effect of aspirin discontinuation on lactate dehydrogenase (LDH) levels and the incidence of bleeding/thrombotic complications.
Gastrointestinal (GI) bleeding, primarily manifesting as angiodsyplasia (AGD) is one of the most common and challenging complications post CF LVAD. The possible mechanisms underlying LVAD induced AGD formation are the subject of intense research efforts and have focused on an association with low or absent pulsatility and acquired type 2A von Willebrand factor deficiency (vWD). We have previously reported a high prevalence of nasal mucosal vascular malformations, a possible surrogate marker for AGD, in patients with heart failure (HF) prior to LVAD implant.
Bleeding is common among patients with left ventricular assist devices (LVADs). It has been recently shown in single center studies that angiopoietin-2 (Ang-2) and Tissue Necrosis Factor- α (TNF-α) are critically linked with bleeding in LVAD patients. The purpose of this study was to describe the changes in plasma levels of angiogenic and inflammatory biomarkers and correlate them with clinical outcome in patients enrolled in the PREVENT study.